Ciena Corporation (CIEN)
NYSE: CIEN · Real-Time Price · USD
92.95
+1.88 (2.06%)
At close: Jul 30, 2025, 4:00 PM
93.61
+0.66 (0.71%)
Pre-market: Jul 31, 2025, 6:31 AM EDT
Marinus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts that cover Marinus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $84.08, which forecasts a -9.54% decrease in the stock price over the next year. The lowest target is $67 and the highest is $105.
Price Target: $84.08 (-9.54%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Marinus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 5 | 5 | 5 | 4 | 5 | 4 |
| Sell | 0 | 0 | 0 | 1 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $83 → $105 | Buy | Maintains | $83 → $105 | +12.96% | Jul 17, 2025 |
| Morgan Stanley | Morgan Stanley | Hold → Sell Downgrades $73 → $70 | Hold → Sell | Downgrades | $73 → $70 | -24.69% | Jul 8, 2025 |
| Wolfe Research | Wolfe Research | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jul 8, 2025 |
| UBS | UBS | Hold Maintains $73 → $78 | Hold | Maintains | $73 → $78 | -16.08% | Jun 6, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $44 → $73 | Hold | Maintains | $44 → $73 | -21.46% | Jun 6, 2025 |
Financial Forecast
Revenue This Year
4.67B
from 4.01B
Increased by 16.36%
Revenue Next Year
5.15B
from 4.67B
Increased by 10.15%
EPS This Year
2.31
from 0.58
Increased by 297.66%
EPS Next Year
3.39
from 2.31
Increased by 47.04%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.8B | 5.5B | 6.0B | ||
| Avg | 4.7B | 5.1B | 5.6B | ||
| Low | 4.5B | 4.8B | 5.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20.4% | 17.3% | 15.6% | ||
| Avg | 16.4% | 10.1% | 9.3% | ||
| Low | 11.5% | 3.4% | 0.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.54 | 3.76 | 5.09 |
| Avg | 2.31 | 3.39 | 4.44 |
| Low | 2.16 | 2.96 | 3.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 338.1% | 63.0% | 50.2% |
| Avg | 297.7% | 47.0% | 30.9% |
| Low | 271.7% | 28.4% | 14.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.